WebDoctor Encyclopedia

Cutaneous sarcomas

Kaposi sarcoma

Kaposi sarcoma is a cancer of the cells lining blood and lymph vessels, caused by human herpesvirus 8 (KSHV). It appears as purple, red or brown patches, plaques or nodules on the skin and mucous membranes.

Medically reviewed Last reviewed October 21, 2026

What is Kaposi sarcoma?

Kaposi sarcoma (KS) is a cancer that starts in the cells lining small blood and lymph vessels. It usually shows up as purple, red or brown patches, plaques or lumps on the skin, but it can also affect the mouth, lymph nodes, lungs and digestive tract.

KS is caused by infection with Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8 (HHV-8). The virus alone is not enough: most people who carry it never develop KS. The cancer appears mainly when the immune system is weakened or, in older people, when immune control of the virus gradually declines.

The disease was first described in 1872 by the Hungarian dermatologist Moritz Kaposi. It remained rare until the HIV/AIDS epidemic of the 1980s, when it became one of the best-known AIDS-defining illnesses.

Today, KS can usually be controlled. Effective HIV treatment, careful adjustment of transplant medicines and a range of local and systemic therapies mean that many people live with KS for years or see their lesions disappear.

1. Epidemiology

KS is uncommon in the general population of Europe and North America. Its frequency depends mainly on two things: how common HHV-8 infection is in a region, and how many people have weakened immunity.

HHV-8 is spread mostly through saliva. Infection is common in much of sub-Saharan Africa, where more than half of adults carry the virus in some areas. It is intermediate in Mediterranean countries and uncommon (well under 10 % of adults) in northern Europe and North America.

Since effective antiretroviral therapy (ART) became widely available in the mid-1990s, KS has become much less common among people with HIV in high-income countries. It remains one of the most frequent cancers in parts of eastern and southern Africa.

Form Who is mainly affected Main risk factors
Classic Older men (usually over 60) of Mediterranean, Eastern European, Middle Eastern or Ashkenazi Jewish descent Older age, male sex, HHV-8 infection, ancestry from regions where the virus is more common
Endemic (African) Children and adults, especially men, in sub-Saharan Africa, regardless of HIV status High regional HHV-8 prevalence, infection early in life
Iatrogenic (transplant-associated) Organ transplant recipients and others taking immunosuppressive drugs HHV-8 infection plus drug-induced immunosuppression
Epidemic (AIDS-related) People living with HIV, historically most often men who have sex with men HIV infection, HHV-8 co-infection, low CD4 count, lack of effective ART
Non-epidemic KS in MSM (proposed fifth form) HIV-negative men who have sex with men HHV-8 infection; usually no immune deficiency

Key points

  • HHV-8 is found in virtually all KS lesions, whatever the form. It is a necessary cause of the disease.
  • Most people infected with HHV-8 never develop KS. Immune status, age and probably genetic factors determine who does.
  • In every form except the classic one, KS is linked to some degree of immune weakness.

2. Causes and How the Disease Develops

2.1 The role of HHV-8

HHV-8 was discovered in 1994, when researchers identified herpesvirus-like DNA sequences in KS tissue from people with AIDS. It was later confirmed to be the cause of KS and of two other conditions: primary effusion lymphoma and multicentric Castleman disease.

After infection, the virus stays in the body for life in a latent (dormant) state. Inside infected cells it produces proteins that copy or hijack normal cell signals. Examples include LANA (latency-associated nuclear antigen), viral cyclin, viral FLIP, viral interleukin-6 and a viral G-protein-coupled receptor.

Together these proteins keep infected cells alive, push them to divide and stimulate the growth of new blood vessels (angiogenesis).

2.2 The role of the immune system

A healthy immune system, especially its T cells, keeps HHV-8 in check. When this control weakens, infected cells can multiply and form tumours.

  • In HIV infection, loss of CD4 T cells and chronic immune activation allow KS to develop and spread.
  • In transplant recipients, drugs that prevent organ rejection also reduce immune control of the virus.
  • In classic KS, the gradual decline of immunity with age is thought to play a part.

2.3 The tumour microenvironment

KS lesions are a mixture of tumour cells and inflammatory cells. The typical tumour cell is a spindle-shaped cell of endothelial (vessel-lining) origin that carries HHV-8.

Inflammatory cells and infected cells release growth factors and cytokines such as VEGF and basic fibroblast growth factor. These feed the growth of fragile new vessels, which is why lesions look purple and can bleed easily.

3. Clinical Forms of Kaposi Sarcoma

The four classic forms look alike under the microscope, but they differ in who they affect and how they behave.

Form Typical patient Usual course Common sites
Classic KS Older men of Mediterranean, Eastern European or Middle Eastern descent Slow-growing over years or decades; rarely life-threatening Lower legs, ankles and feet; internal organs only occasionally
Endemic (African) KS Children and adults in sub-Saharan Africa Ranges from slow skin disease in adults to an aggressive lymph node form in young children Skin of the limbs, lymph nodes; internal organs in aggressive forms
Iatrogenic KS Organ transplant recipients and other people on immunosuppressive drugs Often improves or disappears when immunosuppression is reduced Skin, mouth, and in some cases lymph nodes and internal organs
Epidemic (AIDS-related) KS People living with HIV Can progress quickly without treatment; usually responds to ART with or without chemotherapy Skin anywhere on the body, mouth, lymph nodes, lungs and gut
KS in HIV-negative MSM HIV-negative men who have sex with men Usually slow-growing, similar to classic KS Mainly the skin, often of the limbs

The forms overlap. For example, a transplant recipient on strong immunosuppression may develop widespread disease that behaves like AIDS-related KS.

4. How does it look?

KS has a characteristic look, but early lesions are easy to mistake for bruises, birthmarks or other skin conditions. A biopsy is always needed to confirm the diagnosis.

4.1 From patch to nodule

KS lesions typically pass through three stages. Several stages are often seen side by side in the same person.

Stage Colour Feel Typical description
Patch (early) Pink, red or purple; may look like a bruise Flat, cannot be felt Often oval and may follow skin creases; easily overlooked
Plaque Deeper violet, purple or brown Raised, firmer to the touch Patches thicken and may merge into larger areas
Nodule / tumour Dark purple or brown Firm, rubbery lumps May ulcerate, crust or bleed; can grow into larger masses and fungating tumours

On pale skin, lesions tend to look red or violet. On darker skin they often look dark brown or almost black, which can delay recognition.

Long-standing lesions on the legs are often accompanied by marked swelling (lymphoedema). The swelling can be out of proportion to the size of the visible lesions.

4.2 Dermoscopic features

Dermoscopy (examination with a lighted magnifier) is not diagnostic, but it can support the suspicion of KS. Typical findings include:

  • Bluish-red to purple coloured areas without clear structure
  • A “rainbow pattern”, a play of multiple colours seen in polarised light, especially in nodules
  • A scaly surface and small brown dots or globules
  • White lines or a whitish collarette around the lesion

4.3 Where lesions appear

Form Usual locations
Classic KS Feet, ankles and lower legs, often on both sides; later the hands and arms
AIDS-related KS Anywhere: legs, trunk, face (especially the nose), behind the ears, genitals; the mouth, particularly the hard palate and gums, is often involved
Iatrogenic KS Skin and mouth; internal organs in a minority
Endemic KS in children Lymph nodes, sometimes with few or no skin lesions

In AIDS-related KS, lesions are usually more numerous, more widely spread and more often involve the mouth and internal organs than in classic KS.

4.4 Appearance inside the body

  • Mouth – Flat or raised purple patches, most often on the hard palate, gums or tongue.
  • Gut – At endoscopy, red-purple flat or raised lesions in the stomach, bowel or rectum. They may bleed or, rarely, cause blockage.
  • Lungs – At bronchoscopy, red or violet flat lesions in the airways. A chest CT often shows nodules and thickening along the bronchi and vessels, sometimes with fluid around the lungs (pleural effusion) and enlarged lymph nodes in the chest.
  • Lymph nodes – Enlarged nodes, sometimes with swelling of the limbs or face because lymph drainage is blocked.

5. Symptoms

KS limited to the skin often causes no symptoms at all apart from the visible spots. Many people first notice a painless discoloured patch on the foot or leg.

Symptoms become more likely as lesions grow, ulcerate or involve deeper tissues and internal organs.

5.1 Skin symptoms

  • Visible spots or lumps – purple, red or brown, usually painless at first
  • Pain – mainly from large nodules, ulcerated lesions or swelling, especially on the soles of the feet, which can make walking difficult
  • Bleeding – lesions are fragile and may bleed after minor injury
  • Ulceration and infection – open lesions can become infected and produce discharge or odour
  • Swelling (lymphoedema) – of the legs, genitals or face, which can be painful and limit movement

5.2 Symptoms from the mouth and internal organs

  • Mouth and throat – discomfort, difficulty chewing or swallowing, bleeding, and in advanced cases trouble speaking or wearing dentures
  • Digestive tract – often silent; when present, abdominal pain, nausea, vomiting, diarrhoea, blood in the stool, anaemia or weight loss
  • Lungs – shortness of breath, cough, coughing up blood, chest pain or fever; lung KS can resemble pneumonia and needs urgent care
  • Lymph nodes – painless enlargement, sometimes with swelling of nearby tissues

5.3 General symptoms

Fever, night sweats, weight loss and tiredness can occur, especially in widespread disease. In people with HIV these symptoms may also come from HIV itself or from infections, so they need careful assessment.

5.4 KS and HIV

KS can be the first sign that someone has HIV. Anyone with suspected KS should therefore be offered an HIV test.

KS usually develops when the CD4 count is low, but it can also occur in people with good CD4 counts who are on effective ART.

Shortly after starting ART, existing KS can temporarily worsen. This is called KS-associated immune reconstitution inflammatory syndrome (IRIS). It needs prompt review because it can be serious, especially when the lungs are involved.

5.5 When to seek medical advice

See a doctor promptly if you notice:

  • a new purple, red or brown patch or lump that does not fade like a bruise within a few weeks
  • unexplained swelling of a leg, the genitals or the face
  • purple spots in the mouth
  • blood in the stool, coughing up blood or new shortness of breath, especially if you have HIV or have had an organ transplant

6. Diagnosis

6.1 Clinical examination

The doctor examines the whole skin, the mouth, the genital area and the lymph nodes. The number, size and location of lesions are recorded, often with photographs, so that later changes can be compared.

6.2 Biopsy

A biopsy of a representative lesion is essential to confirm KS. Under the microscope KS shows spindle-shaped cells, slit-like vascular spaces and leaked red blood cells.

The key confirmatory test is immunohistochemistry for HHV-8 LANA, which is positive in virtually all KS. The tumour cells also carry vessel markers such as CD31, CD34, ERG and the lymphatic marker D2-40 (podoplanin).

The biopsy helps rule out lookalikes such as bruises, haemangiomas, pyogenic granuloma, bacillary angiomatosis, angiosarcoma and melanoma.

6.3 Blood tests

Test Why it is done
HIV test Recommended for everyone with KS
CD4 count and HIV viral load For people with HIV, to assess immune status and treatment
Full blood count To detect anaemia (for example from gut bleeding) and check fitness for chemotherapy
Liver and kidney function Baseline before treatment
Hepatitis B and C tests Before chemotherapy or immunotherapy, and as part of HIV care

HHV-8 antibody tests and blood viral load measurements are mainly research tools. A positive or negative result does not confirm or exclude KS.

6.4 Looking for internal disease

  • Chest X-ray or CT if there are breathing symptoms or extensive disease
  • CT of the abdomen and pelvis if there are abdominal symptoms or widespread disease
  • Endoscopy (upper GI endoscopy and colonoscopy) if there are digestive symptoms, unexplained anaemia or blood in the stool
  • Bronchoscopy if lung KS is suspected and the chest CT is unclear

Lesions inside the gut or airways are often diagnosed by their typical appearance. Biopsy of these sites is not always necessary and may cause bleeding.

7. Staging

KS is not staged with the TNM system used for most cancers. Instead, its extent is described with systems specific to the disease.

The AIDS Clinical Trials Group (ACTG) system, published in 1989, looks at three factors: Tumour extent, Immune system and Systemic illness. Each is scored as good risk (0) or poor risk (1).

Factor Good risk (0) – all of the following Poor risk (1) – any of the following
Tumour (T) Disease confined to the skin and/or lymph nodes, and/or minimal oral disease (flat lesions on the palate) Tumour-related swelling or ulceration; extensive oral KS; KS in the gut; KS in other internal organs
Immune system (I) CD4 count of 200 cells/µL or more CD4 count below 200 cells/µL
Systemic illness (S) No history of opportunistic infections or thrush; no B symptoms; performance status (Karnofsky) of 70 or more History of opportunistic infections or thrush; B symptoms (unexplained fever, night sweats, weight loss over 10 %, or diarrhoea lasting more than two weeks); Karnofsky below 70; other HIV-related illness such as neurological disease or lymphoma

Later analyses suggested that a CD4 cutoff of 150 cells/µL separates outcomes better than 200.

In the ART era, the immune score has become less predictive. Tumour extent and systemic illness matter most: people with both extensive tumour and systemic illness (T1 S1) have the poorest outlook.

7.2 Classic and other non-AIDS KS

There is no universally agreed staging system for classic, endemic or iatrogenic KS. Doctors usually describe:

  • whether disease is localised or widespread on the skin
  • whether it is slow or rapidly progressing
  • whether lymph nodes, mucosa or internal organs are involved
  • whether it causes symptoms such as pain, bleeding or lymphoedema

For classic KS, some centres use a four-stage clinical classification proposed by Brambilla and colleagues. It ranges from limited nodular disease on the lower limbs (stage I) to disseminated disease (stage IV).

8. Treatment

Treatment is tailored to the form of KS, its extent and speed of growth, the person’s immune status and general health, and their own priorities.

KS is often a chronic disease. The main goals are to control lesion growth, relieve symptoms, improve appearance and function, and protect quality of life with as few side effects as possible.

8.1 Treating the underlying cause

AIDS-related KS – antiretroviral therapy

Effective ART is the foundation of treatment for everyone with AIDS-related KS. It should be started as soon as possible or optimised if already in use.

As the immune system recovers, limited KS often shrinks or disappears without any other treatment. For more extensive or symptomatic disease, ART is combined with chemotherapy.

Transplant-associated KS – adjusting immunosuppression

The first step is to reduce immunosuppressive drugs as far as is safe for the transplanted organ. Many patients also switch from a calcineurin inhibitor (such as ciclosporin or tacrolimus) to an mTOR inhibitor such as sirolimus. This drug prevents rejection and also has anti-tumour and anti-angiogenic effects.

In a landmark study of 15 kidney transplant recipients, all skin KS lesions disappeared within three months of switching from ciclosporin to sirolimus.

8.2 Local (lesion-directed) treatments

Local treatments are used for a small number of lesions, for cosmetically troublesome lesions, or to relieve symptoms at a particular site.

Treatment How it works Best suited for Main drawbacks
Observation Regular check-ups without active treatment Few, small, stable lesions without symptoms, especially in classic KS Lesions may slowly grow
Radiotherapy Destroys tumour cells with targeted radiation Painful, bleeding or bulky lesions; lymphoedema-causing disease; areas such as the feet, face or mouth Skin reactions; the mouth and feet can be sensitive
Intralesional vinblastine Chemotherapy injected directly into the lesion Nodules and plaques, including in the mouth Pain at the injection site; repeated sessions may be needed
Alitretinoin 0.1 % gel Topical retinoid (vitamin A derivative) Limited skin lesions in AIDS-related KS (FDA-approved for this use) Skin irritation; slow response; not suitable for thick nodules
Imiquimod cream Stimulates a local immune response Small skin lesions (used off-label, mainly in classic KS) Irritation, redness
Cryotherapy Freezes the lesion with liquid nitrogen Small flat lesions Blistering, pale or dark marks
Surgical excision Removes the lesion Single small lesions KS often recurs at or near the scar; not useful for widespread disease
Laser therapy Seals or destroys abnormal vessels Selected superficial lesions Limited availability; pigment change or scarring

8.3 Systemic treatments

Systemic therapy is used for widespread or rapidly progressing skin disease, painful lymphoedema, symptomatic disease in the mouth, and involvement of internal organs. It is also used when KS does not respond to ART or to reduced immunosuppression.

Treatment Role Common side effects
Pegylated liposomal doxorubicin Standard first-line chemotherapy for advanced KS in many countries; in trials it was more effective and better tolerated than older combination regimens Low blood counts, tiredness, hand-foot skin reaction (redness and peeling of palms and soles), mouth sores; heart effects are less common than with standard doxorubicin
Paclitaxel Active as first-line or second-line therapy; widely used where liposomal doxorubicin is unavailable Low blood counts, hair loss, numbness and tingling (neuropathy), allergic reactions
Pomalidomide Oral immunomodulatory drug; FDA accelerated approval in May 2020 for AIDS-related KS after failure of ART and for KS in HIV-negative adults Low blood counts, tiredness, constipation, rash; blood clots (aspirin is often given); it harms unborn babies, so strict pregnancy prevention is required
Other options Docetaxel, oral etoposide, vinblastine, vinorelbine, gemcitabine, bleomycin with vincristine; interferon alfa in selected cases Depend on the drug

Both liposomal doxorubicin and paclitaxel produce responses in roughly half or more of people with advanced KS on ART. In the phase I/II study that led to its approval, pomalidomide produced responses in about 70 % of patients with and without HIV.

8.4 Treatments under investigation

  • Immune checkpoint inhibitors such as pembrolizumab, and nivolumab with ipilimumab, have shown promising activity in small studies of classic and AIDS-related KS. They are not yet a standard treatment.
  • Antiviral drugs such as ganciclovir and valganciclovir can reduce HHV-8 replication, but they do not shrink established KS lesions. They are not part of routine treatment or prevention.
  • Other targeted therapies and new immunomodulatory drugs are being tested in clinical trials.

8.5 Typical approach by form (simplified)

AIDS-related KS

  1. Start or optimise ART in every case.
  2. For limited skin disease (T0): ART alone, sometimes with local treatment for troublesome lesions.
  3. For extensive or visceral disease (T1), or progression on ART: ART plus systemic chemotherapy, usually liposomal doxorubicin or paclitaxel.
  4. For relapsed or resistant disease: another chemotherapy agent, pomalidomide or a clinical trial.

Transplant-associated KS

  1. Reduce immunosuppression and consider switching to sirolimus, in close cooperation with the transplant team.
  2. Local therapy for remaining skin lesions.
  3. Systemic chemotherapy if disease is widespread, involves internal organs or keeps progressing.

Classic and endemic KS

  1. Observation or local treatment for limited, slow-growing disease.
  2. Systemic therapy (liposomal doxorubicin, paclitaxel, vinblastine or pomalidomide) for widespread, rapidly progressing, symptomatic or visceral disease.
  3. Supportive measures such as compression therapy for lymphoedema and wound care.

9. Prognosis

The outlook for KS varies widely with its form, its extent and, above all, the state of the immune system.

  • Classic KS usually grows slowly over many years. Most people with classic KS die of unrelated causes.
  • AIDS-related KS has changed from a rapidly fatal condition in the 1980s to a largely controllable one. With effective ART and chemotherapy when needed, most people achieve long-term control. The outlook remains poorer with extensive disease and serious HIV-related illness.
  • Transplant-associated KS often regresses after immunosuppression is reduced or changed. Visceral disease and loss of the transplanted organ are the main risks.
  • Endemic KS ranges from slow skin disease to the aggressive lymph node form of young children. Outcomes in Africa are worse, largely because of late diagnosis and limited access to treatment.
Factor Effect on outlook
Immune status Recovery of immune function with ART or reduced immunosuppression greatly improves outcomes
Extent of disease Involvement of the lungs or gut and extensive lymphoedema are linked with a poorer outlook
Systemic illness B symptoms, opportunistic infections and poor general health lower survival in AIDS-related KS
Response to treatment A good response to first treatment is associated with longer disease control
Access to care Late diagnosis and limited access to ART and chemotherapy remain the biggest causes of poor outcomes worldwide

KS can return after successful treatment, especially if the immune system weakens again. Long-term follow-up is therefore important.

10. Prevention

There is no vaccine against HHV-8, and no proven way to eliminate the virus once a person is infected. Prevention focuses on keeping the immune system strong and finding KS early.

Strategy Practical measures
HIV prevention and early ART Regular HIV testing for people at risk; starting ART promptly after diagnosis, regardless of CD4 count; this has sharply reduced KS among people with HIV
Reducing HHV-8 transmission The virus is shed mainly in saliva; avoiding saliva-sharing practices (for example pre-chewing food for children) may reduce spread in high-prevalence regions
Care for transplant recipients Using the lowest effective immunosuppression; regular skin and mouth checks, especially in recipients from regions where HHV-8 is common
Skin surveillance Regular skin and mouth examinations for people with HIV, transplant recipients and others at higher risk

11. Living with Kaposi Sarcoma

  • Skin care – Keep lesions clean and protected. Use non-adhesive dressings on ulcerated areas and avoid friction from tight shoes or clothing.
  • Camouflage – Special cover-up make-up can hide visible lesions on the face or hands and help with self-confidence.
  • Lymphoedema care – Compression bandages or stockings, skin care, gentle exercise and lymphatic drainage by a trained therapist can reduce swelling.
  • Pain relief – Ordinary painkillers help many people. Painful lesions can also be treated directly, for example with radiotherapy.
  • Nutrition – A balanced diet supports recovery. A dietitian can help if mouth or gut lesions make eating difficult or cause weight loss.
  • Emotional support – Visible lesions can cause embarrassment, anxiety or low mood, and KS may carry the stigma attached to HIV. Counselling, peer support groups and HIV support services can help.
  • Follow-up – Regular check-ups are needed, more often during active treatment. People with HIV should keep taking ART consistently, since good HIV control is the best protection against KS returning.

12. Frequently Asked Questions

Question Answer
Is Kaposi sarcoma contagious? No. KS itself cannot be passed from person to person. The HHV-8 virus can be transmitted, mainly through saliva, but most people who carry it never develop KS.
Can KS be cured? KS often goes away completely, particularly in AIDS-related KS treated with ART and in transplant KS after immunosuppression is changed. In other cases it behaves like a chronic disease that can be controlled for many years, although it may return.
Does KS mean I have AIDS? Not necessarily. Classic, endemic and transplant-associated KS occur in people without HIV. In a person with HIV, however, KS is considered an AIDS-defining illness.
Will treatment make me lose my hair? Paclitaxel usually causes hair loss. Liposomal doxorubicin and pomalidomide cause it much less often. Local treatments do not.
Can I exercise with KS lesions on my legs? Yes. Gentle activity is encouraged and helps with lymphoedema. Protect lesions from friction and injury, and wear compression garments if they are recommended.
Is there a vaccine against HHV-8? No. Research is ongoing, but no vaccine is currently available.

13. Conclusion

Kaposi sarcoma shows clearly how a virus and the immune system together shape the course of a cancer. HHV-8 is the essential cause, but immune weakness, from HIV, transplant medicines or ageing, decides when the disease appears and how it behaves.

Once a feared sign of advanced AIDS, KS is now usually a controllable condition. Effective HIV treatment, adjustment of immunosuppression, local therapies, liposomal doxorubicin, paclitaxel and pomalidomide give most patients good options.

Recognising the typical purple patches, plaques and nodules early, confirming them with a biopsy and checking HIV status are the key first steps.

Resources

  1. Cesarman, E. et al. (2019) ‘Kaposi sarcoma’, Nature Reviews Disease Primers, 5, 9.
  2. Chang, Y. et al. (1994) ‘Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma’, Science, 266(5192), pp. 1865-1869.
  3. Krown, S.E., Metroka, C. and Wernz, J.C. (1989) ‘Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria’, Journal of Clinical Oncology, 7(9), pp. 1201-1207.
  4. Nasti, G. et al. (2003) ‘AIDS-related Kaposi’s sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group staging system in the HAART era’, Journal of Clinical Oncology, 21(15), pp. 2876-2882.
  5. Stallone, G. et al. (2005) ‘Sirolimus for Kaposi’s sarcoma in renal-transplant recipients’, New England Journal of Medicine, 352(13), pp. 1317-1323.
  6. Polizzotto, M.N. et al. (2016) ‘Pomalidomide for symptomatic Kaposi’s sarcoma in people with and without HIV infection: a phase I/II study’, Journal of Clinical Oncology, 34(34), pp. 4125-4131.
  7. Lebbe, C. et al. (2019) ‘Diagnosis and treatment of Kaposi’s sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)’, European Journal of Cancer, 114, pp. 117-127.
  8. National Cancer Institute (2026) Kaposi Sarcoma Treatment (PDQ®) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/kaposi-treatment-pdq (Accessed: October 2026).
  9. American Cancer Society (2026) Kaposi Sarcoma. Available at: https://www.cancer.org/cancer/types/kaposi-sarcoma.html (Accessed: October 2026).

Prepared by the editorial team, October 2026.